3 results
To assess the safety and tolerability profile of durvalumab monotherapy, durvalumab + novel oncology therapy, durvalumab + chemotherapy, anddurvalumab + novel oncology therapy + chemotherapy combinations
The primary objective of the study is:- To evaluate the pharmacodynamics effects on follicular growth and ovulation of one dose of 30 mg UPA taken before dominant follicle selectionThe secondary objectives are:- To determine the pharmacokinetics…
The primary objective of this study is:• To evaluate whether simtuzumab (formally referred to as GS-6624) is effective at preventing the progression of liver fibrosis in subjects with PSC.The secondary objectives of this study include the following…